Skip to main content

Aptensio XR® Capsules, CII

STRENGTH PACK
10 mg 90 (Bottle)
15 mg 90 (Bottle)
20 mg 90 (Bottle)
30 mg 90 (Bottle)
40 mg 90 (Bottle)
50 mg 90 (Bottle)
60 mg 90 (Bottle)

Important Safety Information

 

 

 

 

 

 

Buprenorphine and Naloxone Sublingual Tablets, CIII

STRENGTH PACK
2mg/ 0.5mg 30 (Bottle)
8mg/ 2mg 30 (Bottle)

Important Safety Information

Buprenorphine Sublingual Tablets, CIII

STRENGTH PACK
2 mg 30 (Bottle)
8 mg 30 (Bottle)

Important Safety Information

BOXED WARNING/IMPORTANT SAFETY INFORMATION: 

WARNINGS AND PRECAUTIONS 

WARNING: ADDICTION, ABUSE and MISUSE; RISK EVALUATION AND MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS 

 Addiction, Abuse, and Misuse: Buprenorphine can be abused in a similar manner to other opioids. Monitor patients for conditions indicative of diversion or progression of opioid dependence and addictive behaviors. Multiple refills should not be prescribed early in treatment or without appropriate patient follow-up visits. (5.1) 

Respiratory Depression: Life-threatening respiratory depression and death have occurred in association with buprenorphine use. Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with buprenorphine sublingual tablets (5.2, 5.3). 

Unintentional Pediatric Exposure: Store buprenorphine sublingual tablets safely out of the sight and reach of children. Buprenorphine can cause severe, possibly fatal, respiratory depression in children. (5.4) 

Neonatal Opioid Withdrawal Syndrome: Neonatal opioid withdrawal syndrome (NOWS) is an expected and treatable outcome of prolonged use of opioids during pregnancy. (5.5) 

Adrenal Insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids and wean patient off of the opioid. (5.6) 

Risk of Opioid Withdrawal with Abrupt Discontinuation: If treatment is temporarily interrupted or discontinued, monitor patients for withdrawal and treat appropriately. (5.7) 

Risk of Hepatitis, Hepatic Events: Monitor liver function tests prior to initiation and during treatment and evaluate suspected hepatic events. (5.8) 

Precipitation of Opioid Withdrawal Signs and Symptoms: An opioid withdrawal syndrome is likely to occur with parenteral misuse of buprenorphine sublingual tablets by individuals physically dependent on full opioid agonists, or by sublingual administration before the agonist effects of other opioids have subsided. (5.10) 

Risk of Overdose in Opioid-Naïve PatientsBuprenorphine sublingual tablets are NOT appropriate as an analgesic. There have been reported deaths of opioid naïve individuals who received a 2 mg sublingual dose of buprenorphine. (5.11) 

Buprenorphine Transdermal System, CIII

STRENGTH PACK
5 mcg 4 (Carton)
7.5 mcg 4 (Carton)
10 mcg 4 (Carton)
15 mcg 4 (Carton)
20 mcg 4 (Carton)

Important Safety Information

Dexmethylphenidate Hydrochloride Tablets, CII

STRENGTH PACK
2.5 mg 100 (Bottle)
5 mg 100 (Bottle)
10 mg 100 (Bottle)

Important Safety Information

DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE

STRENGTH PACK
5 100 (Bottle)
7.5 100 (Bottle)
10 100 (Bottle)
12.5 100 (Bottle)
15 100 (Bottle)
20 100 (Bottle)
30 100 (Bottle)

Important Safety Information

DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE EXTENDED-RELEASE, CII

STRENGTH PACK
5 mg 100 (Bottle)
10 mg 100 (Bottle)
15 mg 100 (Bottle)
20 mg 100 (Bottle)
25 mg 100 (Bottle)
30 mg 100 (Bottle)

Important Safety Information

Dilaudid® (hydromorphone HCl) Oral Solution, USP, CII

STRENGTH PACK
1 mg/mL 1 (Bottle)

Important Safety Information

Dilaudid® (hydromorphone HCl) Tablets, USP, CII

STRENGTH PACK
2 mg 100 (Bottle)
4 mg 100 (Bottle)
4 mg 500 (Bottle)
8 mg 100 (Bottle)

Important Safety Information

Dronabinol Capsules, USP, CIII

STRENGTH PACK
2.5 mg 60 (Bottle)
5 mg 60 (Bottle)
10 mg 60 (Bottle)

Important Safety Information

Privacy Policy Updates

Please read carefully the Purdue Pharma L.P. Privacy Policy (the “Privacy Policy”), which is part of the Purdue Pharma L.P. Terms and Conditions, before you access, download, or otherwise use any of our websites, related other parities’ websites, mobile applications, or any electronic service (collectively, the “Service”). This Privacy Policy describes the information collected through Your use of the Service, how we use it, how we share it, how we protect it, and the choices You can make about Your information.

Bitnami